Q2 FY2026 EarningsQ2 FY2026 revenue was in-line with consensus at $498.1M vs. $498.8M expected, while GAAP EPS missed expectations at -$0.41 vs. -$0.41 (though the net loss of $75M was deeper than some forecasts). Adjusted EBITDA improved sequentially to $69.4M (14% margin), driven by the Stimulation Services segment. Q3 guidance suggests sequential improvement in Stimulation Services due to pricing increases, though the Proppant segment faces persistent pricing pressure.